<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264676</url>
  </required_header>
  <id_info>
    <org_study_id>KY2019-066</org_study_id>
    <nct_id>NCT04264676</nct_id>
  </id_info>
  <brief_title>Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer</brief_title>
  <official_title>Fusobacterium Nucleatum Eradication in Postoperative Stage II/III Colorectal Cancer(FINER-PACE)by Oral Metronidazole: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Municipal Commission of Health and Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Shenkang Hospital Development Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fusobacterium nucleatum (Fusobacterium nucleatum, Fn) has been identified as an independent&#xD;
      risk factor for recurrence of colorectal cancer. In this study, oral metronidazole would be&#xD;
      used to reduce the abundance of Fn in patients with high Fn, so as to explore whether oral&#xD;
      metronidazole can improve the efficacy of postoperative chemotherapy in patients with&#xD;
      colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota are linked to chronic inflammation and carcinogenesis. Chemotherapy failure is&#xD;
      the major cause of recurrence and poor prognosis in colorectal cancer patients. Previously in&#xD;
      the investigators' research, the investigators find the contribution of gut microbiota to&#xD;
      chemoresistance in patients with colorectal cancer. The investigators found that&#xD;
      Fusobacterium nucleatum (Fn) was abundant in colorectal cancer tissues in patients with&#xD;
      recurrence post chemotherapy, and was associated with patient clinicopathological&#xD;
      characterisitcs. Furthermore, the investigators' bioinformatic and functional studies&#xD;
      demonstrated that Fn promoted colorectal cancer resistance to chemotherapy. Metronidazole has&#xD;
      been known to treat with anaerobe infection, including Fusobacterium. So oral metronidazole&#xD;
      would be used to reduce the abundance of Fn in patients with high Fn, so as to explore&#xD;
      whether oral metronidazole can improve the efficacy of postoperative chemotherapy in patients&#xD;
      with colorectal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival, DFS</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the initial surgical treatment of colorectal cancer to the earliest evidence of recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, OS</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the initial surgical treatment of colorectal cancer to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Rate, RR</measure>
    <time_frame>3 years, 5 years</time_frame>
    <description>Percentage of patients who has recurrence during or after chemotherapy with Metronidazole or Placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Colorectal Cancer Stage II</condition>
  <condition>Colorectal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>supplement of metronidazole 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6(6 treatments totally),and every 6 weeks for CapeOX (4 treatments totally).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>supplement of identical-appearing placebo 0.4g three times per day for 7 days, which is one treatment every 4 weeks for mFOLFOX6 (6 treatments totally),and every 6 weeks for CapeOX 4 treatments totally).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Oral Tablet</intervention_name>
    <description>Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.</description>
    <arm_group_label>Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals aged 18-75 years&#xD;
&#xD;
          -  Individuals firstly confirmed by surgery pathology as colorectal cancer (AJCC cancer&#xD;
             staging II - III), who need mFOLFOX6 or CapeOX postoperative chemotherapy&#xD;
&#xD;
          -  Individuals with Fn - deltaCT value in colon tissue samples detected by qPCR ≥-12&#xD;
             before receiving chemotherapy&#xD;
&#xD;
          -  Individuals who could tolerate chemotherapy drugs: ECOG (Eastern Cooperative Oncology&#xD;
             Group) score ≤2 points, WBC(White Blood Cell) ≥4.0×10^9/L, Hb （Hemoglobin） ≥80g/L, PLT&#xD;
             （Platelet） ≥80×10^9/L, ALT （Alanine Aminotransferase）&lt; 2ULN （Upper Limmit of Normal）,&#xD;
             Scr （Creatinine）&lt; 1.5ULN&#xD;
&#xD;
          -  Individuals who participate this study and sign the informed consent form willingly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with colorectal adenoma or non-colorectal cancer, such as inflammatory&#xD;
             bowel disease&#xD;
&#xD;
          -  Individuals with a history of familial adenomatous polyposis (FAP)&#xD;
&#xD;
          -  Individuals with severe heart, lung, brain, kidney, gastrointestinal or systemic&#xD;
             diseases&#xD;
&#xD;
          -  Individuals who used antibiotics for more than 5 days in 1 month prior to chemotherapy&#xD;
&#xD;
          -  Individuals with stage I or IV colorectal cancer, or with stage II colorectal cancer&#xD;
             who do not need postoperative chemotherapy&#xD;
&#xD;
          -  Individuals with contraindications for metronidazole&#xD;
&#xD;
          -  Individuals who unwilling to participate this study，or unwilling to sign the informed&#xD;
             consent form&#xD;
&#xD;
          -  Individuals with any conditions that the researchers considered inappropriate for&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingyuan Fang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingyuan Fang, MD, PhD</last_name>
    <phone>86-021-58752345</phone>
    <email>jingyuanfang@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danfeng Sun, PhD</last_name>
    <phone>86-021-58752345</phone>
    <email>danfolsdf@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology &amp; Hepatology, Ministry of Health</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing-Yuan Fang, MD. Ph D.</last_name>
    </contact>
    <investigator>
      <last_name>Jing-Yuan Fang, MD. Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Shi, MD. Ph D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjun Cai, MD. Ph D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianyong Sun, MD. Ph D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 8, 2020</study_first_submitted>
  <study_first_submitted_qc>February 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jing-yuan Fang, MD, Ph. D</investigator_full_name>
    <investigator_title>Director of Department of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Metronidazole</keyword>
  <keyword>Gut Microbiota</keyword>
  <keyword>Postoperative Chemotherapy</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Fusobacterium nucleatum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

